Last reviewed · How we verify

NCT03052465: MIC2

Magnetic Resonance Imaging of Motility in Crohn's 2

Completed NA Last updated 25 October 2017
What this trial tests

NA trial testing Test soup meal feeding intervention in Crohn Disease in 36 participants. Completed in 7 March 2017.

Timeline
16 November 2015
Primary endpoint
7 March 2017
7 March 2017

Quick facts

Lead sponsorUniversity of Nottingham
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment36
Start date16 November 2015
Primary completion7 March 2017
Estimated completion7 March 2017
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Nottingham

Who can join

Adults 18 to 75, any sex, with Crohn Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Crohn's disease (CD) is becoming more common. One of the main features of this disease is weight loss and malnutrition with symptoms such as tummy aches and bloating. These problems have a strong negative effect on the patients' quality of life but the causes of these problems are not well understood. Enteroendocrine cells are nutrient sensors in the bowel that secrete special chemicals (called hormones) that control appetite and the movements all the gut. The investigators think that this control mechanism goes wrong in Crohn's patients and they have set off to do more research on this. Looking at the inside work of the gut has always been difficult and at times unpleasant for patients, however recent developments in magnetic resonance imaging (MRI) are allowing the investigators to study the workings of the gut in greater detail and without discomfort for the patients. Our main objective is to investigate the difference in small bowel motility between CD patients with active ileal disease and healthy volunteers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Gastrointestinal peptides and small-bowel hypomotility are possible causes for fasting and postprandial symptoms in active Crohn's disease.
    Khalaf A, Hoad CL, Menys A, Nowak A, et al · · 2020 · cited 18× · PMID 31557279 · DOI 10.1093/ajcn/nqz240

Verify or expand the search:

Other recruiting trials for Crohn Disease

Currently open trials in the same condition.

Other University of Nottingham trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03052465.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing